Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030634 | 0.89 | MAOA (0.41) | MAOAPOLBADORA3XDH | |
| SCHEMBL11029063 | 0.87 | MAOA (0.40) | MAOAADORA3NPC1RAB9A | |
| SCHEMBL11029434 | 0.85 | MAOA (0.42) | MAOAADORA3 | |
| SCHEMBL11031301 | 0.83 | MAOA (0.64) | MAOAMGAMNPC1RAB9ATOP2A | |
| SCHEMBL20567294 | 0.78 | L3MBTL1 (0.57) | POLBNPC1RAB9A | |
| SCHEMBL31060715 | 0.77 | MAOA (0.68) | MAOAPOLBADORA3NPC1RAB9A | |
| SCHEMBL11029477 | 0.77 | MAOA (0.68) | MAOAPOLBADORA3NPC1RAB9A | |
| SCHEMBL11028089 | 0.76 | MAOA (0.47) | MAOAPOLBADORA3MGAMGAA | |
| SCHEMBL11028326 | 0.75 | MAOA (0.46) | MAOAPOLBADORA3MGAMGAA | |
| SCHEMBL20568031 | 0.75 | PTGS1 (0.42) | POLBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | claimed |
| US-8846749-B2 | Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | ABCC1, ANXA1, ANXA5 | MAOA 4052/4885POLB 1806/4885ADORA3 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.